BRPI0720114A8 - Uso de um antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados, método para tratar caquexia, e, antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados - Google Patents

Uso de um antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados, método para tratar caquexia, e, antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados

Info

Publication number
BRPI0720114A8
BRPI0720114A8 BRPI0720114A BRPI0720114A BRPI0720114A8 BR PI0720114 A8 BRPI0720114 A8 BR PI0720114A8 BR PI0720114 A BRPI0720114 A BR PI0720114A BR PI0720114 A BRPI0720114 A BR PI0720114A BR PI0720114 A8 BRPI0720114 A8 BR PI0720114A8
Authority
BR
Brazil
Prior art keywords
antagonist
ht1a
partial agonist
adrenergic
combined beta
Prior art date
Application number
BRPI0720114A
Other languages
English (en)
Inventor
Cavalla David
Original Assignee
Actimed Therapeutics Ltd
Myotec Therapeutics Ltd
Psixus Therapeutics Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Actimed Therapeutics Ltd, Myotec Therapeutics Ltd, Psixus Therapeutics Ltd filed Critical Actimed Therapeutics Ltd
Publication of BRPI0720114A2 publication Critical patent/BRPI0720114A2/pt
Publication of BRPI0720114A8 publication Critical patent/BRPI0720114A8/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4704—2-Quinolinones, e.g. carbostyril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/06—Anabolic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Urology & Nephrology (AREA)
  • Neurology (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • AIDS & HIV (AREA)
  • Vascular Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Hospice & Palliative Care (AREA)
  • Nutrition Science (AREA)
  • Immunology (AREA)

Abstract

USO DE UM ANTAGONISTA BETA-ADRENÉRGICO E ANTAGONISTA OU AGONISTA PARCIAL DE 5-HT1A COMBINADOS, E, ANTAGONISTA BETA-ADRENÉRGICO E ANTAGONISTA OU AGONISTA PARCIAL DE 5-HT1A COMBINADOS A presente invenção diz respeito a meios para a prevenção e tratamento de caquexia e outras enfermidades crônicas incluindo, mas sem limitações, a promoção de ganho de peso, redução ou prevenção de perda de peso pela administração de uma substância que reduz a sensibilidade tanto de receptores beta-adrenérgicos quanto de receptores 5-HT1a. (S)-pindolol, (S)- propanolol, tertatolol ou bopindolol são usados para este propósito.
BRPI0720114A 2006-12-05 2007-12-05 Uso de um antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados, método para tratar caquexia, e, antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados BRPI0720114A8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB0624282.0A GB0624282D0 (en) 2006-12-05 2006-12-05 Treatment of cachexia
GB0624282.0 2006-12-05
PCT/GB2007/004644 WO2008068477A1 (en) 2006-12-05 2007-12-05 Treatment of cachexia

Publications (2)

Publication Number Publication Date
BRPI0720114A2 BRPI0720114A2 (pt) 2014-04-15
BRPI0720114A8 true BRPI0720114A8 (pt) 2016-01-19

Family

ID=37671884

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0720114A BRPI0720114A8 (pt) 2006-12-05 2007-12-05 Uso de um antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados, método para tratar caquexia, e, antagonista beta-adrenérgico e antagonista ou agonista parcial de 5-ht1a combinados

Country Status (16)

Country Link
US (1) US8716325B2 (pt)
EP (2) EP2094254B1 (pt)
JP (1) JP5166437B2 (pt)
CN (1) CN101610760B (pt)
AT (1) ATE513543T1 (pt)
AU (1) AU2007330607B2 (pt)
BR (1) BRPI0720114A8 (pt)
CA (1) CA2671622C (pt)
DK (1) DK2094254T3 (pt)
ES (1) ES2395244T3 (pt)
GB (1) GB0624282D0 (pt)
PL (1) PL2094254T3 (pt)
PT (1) PT2094254E (pt)
RU (1) RU2485950C2 (pt)
WO (1) WO2008068477A1 (pt)
ZA (1) ZA200904704B (pt)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0907350D0 (en) 2009-04-29 2009-06-10 Myotec Therapeutics Ltd Methods
BR112015001712A2 (pt) * 2012-07-25 2017-07-04 Psioxus Therapeutics Ltd uso de s-pindolol para o tratamento da caquexia e sarcopenia
HRP20182041T1 (hr) * 2013-03-14 2019-02-08 Actimed Therapeutics Ltd Pripravci oksprenolola za liječenje raka
US11096908B2 (en) 2016-02-26 2021-08-24 Actimed Therapeutics Ltd S-enantiomerically enriched compositions of beta blockers for treating muscle weakness
GB2593902B (en) 2020-04-07 2022-04-13 Actimed Therapeutics Ltd Salt of a pharmaceutical compound
GB202114564D0 (en) 2021-10-12 2021-11-24 Actimed Therapeutics Ltd Oral formulation
WO2025222169A1 (en) 2024-04-19 2025-10-23 Faraday Pharmaceuticals, Inc. S-oxprenolol for preserving muscle mass, bone density, and cardiac function in weight loss treatments

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541188A (en) 1987-09-15 1996-07-30 The Rowett Research Institute Therapeutic applications of beta-adrenergic agonists
CA1337432C (en) 1988-03-23 1995-10-24 Raymond M. Xhonneux Method of lowering the blood pressure
US6545040B1 (en) 1988-03-23 2003-04-08 Janssen Pharmaceutica N.V. Method of lowering the blood pressure
CA2025398A1 (en) 1989-09-20 1992-03-15 Timothy Gerard Dinan Diagnosis and treatment of a disorder of the gastrointestinal tract
US5120791A (en) 1990-07-27 1992-06-09 Lisco, Inc. Golf ball cover compositions
DE69942009D1 (de) 1998-10-15 2010-03-25 Imp Innovations Ltd Verbindungen für die behandlung von gewichtsverlust
HUP0204262A2 (hu) 2000-01-31 2003-04-28 Pfizer Products Inc. Benzogyűrűvel kondenzált heterociklusos csoportot tartalmazó nikotinamid-származékok, továbbá e vegyületeket tartalmazó, a PDE4 izozimek szelektív gátlására adható gyógyászati készítmények
AR030414A1 (es) * 2000-04-03 2003-08-20 Astrazeneca Ab Combinacion farmaceutica que comprende un beta bloqueante y un inhibidor de hmg-coa reductasa , formulacion farmaceutica, equipo transportable de partes , uso de esta combinacion y de esta formulacion para preparar medicamentos
WO2003065970A2 (en) * 2001-02-20 2003-08-14 Royal College Of Surgeons Ie Treatment of fibromyalgia and related fatigue syndromes using pindolol
US6670140B2 (en) * 2001-03-06 2003-12-30 The Procter & Gamble Company Methods for identifying compounds for regulating muscle mass or function using corticotropin releasing factor receptors
WO2006030306A2 (en) * 2004-09-17 2006-03-23 Neurocure Ltd Pindolol for treating premenstrual syndrome and premenstrual dysphoric disorder
US20060069086A1 (en) 2004-09-23 2006-03-30 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CA2646131C (en) 2005-03-21 2018-09-04 Vicus Therapeutics Spe 1, Llc Compositions and methods for ameliorating cachexia
MX2008007790A (es) 2005-12-22 2009-03-04 Anaborex Inc Composiciones y metodos para la prevencion y tratamiento de caquexia.
WO2007100775A2 (en) 2006-02-27 2007-09-07 Alexander Michalow Methods for regulating neurotransmitter systems by inducing counteradaptations
CL2007003227A1 (es) 2006-11-09 2008-07-04 Boehringer Ingelheim Int Composicion farmaceutica que comprende un derivado de benceno sustituido con glucopiranosilo en combinacion con uno o mas agentes terapeuticos; y uso para el tratamiento de diabetes mellitus, obesidad e hiperglucemia entre otras.
KR101546977B1 (ko) 2007-04-24 2015-08-24 아카시아 파마 리미티드 근육 손실의 치료에서의 약물 조합 및 그것의 용도
CA2753844A1 (en) 2008-03-05 2009-09-11 Vicus Therapeutics, Llc Compositions and methods for mucositis and oncology therapies

Also Published As

Publication number Publication date
ES2395244T3 (es) 2013-02-11
CA2671622C (en) 2015-01-27
EP2359822B1 (en) 2016-08-03
AU2007330607A1 (en) 2008-06-12
US8716325B2 (en) 2014-05-06
JP5166437B2 (ja) 2013-03-21
EP2094254A1 (en) 2009-09-02
DK2094254T3 (da) 2011-10-03
EP2359822A1 (en) 2011-08-24
AU2007330607B2 (en) 2013-02-07
EP2094254B1 (en) 2011-06-22
ZA200904704B (en) 2010-05-26
WO2008068477A1 (en) 2008-06-12
RU2009125548A (ru) 2011-01-20
PL2094254T3 (pl) 2011-12-30
CA2671622A1 (en) 2008-06-12
CN101610760A (zh) 2009-12-23
RU2485950C2 (ru) 2013-06-27
GB0624282D0 (en) 2007-01-10
US20100292270A1 (en) 2010-11-18
JP2010511685A (ja) 2010-04-15
CN101610760B (zh) 2012-09-26
ATE513543T1 (de) 2011-07-15
BRPI0720114A2 (pt) 2014-04-15
PT2094254E (pt) 2011-09-19

Similar Documents

Publication Publication Date Title
JOP20230272A1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
JOP20200277B1 (ar) مركبات تثبيط rip1 وطرق لتحضير واستخدامها
EA201100133A1 (ru) Антагонисты рецепторов простагландина d
EA201170473A1 (ru) Морфинановые соединения
UA98839C2 (en) N,n-disubstituted aminoalkylbiphenyl antagonists of prostaglandin d2 receptors
UY32225A (es) Antagonistas de cicloalcano[b]azaindol de los receptores de la prostaglandina d2
MX384206B (es) Formulaciones de inhibidores de dpp iv
SV2009003299A (es) Derivados de dihidropiridina de utilidad como inhibidores de la proteina quinasa
MA32934B1 (fr) Combinaisons inhibitrices hsp90
HN2008001720A (es) Arilimidazolonas y ariltriazolonas sustituidas como inihibidores de receptores de vasopresina
EA200900203A1 (ru) Избирательные модуляторы рецептора андрогенов, их аналоги, производные и применение
EA201100426A1 (ru) Бициклические ингибиторы киназы
BRPI0516483A (pt) preparo e uso de derivados de ácido bifenil-4-il-carbonilamino para o tratamento de obesidade
EA200800441A1 (ru) Замещенные бензимидазолы в качестве ингибиторов киназ
DOP2010000304A (es) Composiciones y metodos de preparacion y uso de las mismas
BR112013004368A2 (pt) compostos tendo a fórmula geral (i) e composição farmacêutica
BR112012028136A2 (pt) terapia de combinaçao
EA201001253A1 (ru) N,n-дизамещенные аминоалкилбифенилы в качестве антагонистов рецепторов простагландина d
CR11684A (es) Dihidropirazolonas sustituidas de hif-propil-4- como inhibidores hidroxilasa
EA201001747A1 (ru) Бензоксазиноновые производные, действующие в качестве агониста бета-2-адренорецептора, для лечения респираторных расстройств
CL2011001331A1 (es) Clorhidrato de nalmefeno dihidratado; métodos para su preparación; composición farmacéutica que lo comprende; y uso para el tratamiento del alcoholismo.
CL2008000021A1 (es) Compuestos derivados de 2,4-dianilinopirimidinas, inhibidores de proteinas cinasas; procedimiento de preparacion; composicion farmaceutica; y uso para el tratamiento o prevencion de enfermedades inflamatorias, diabetes y cancer.
CL2011001232A1 (es) Combinacion farmaceutica que comprende un anticuerpo que reconoce especificamente la cd38 y al menos citarabina; y su uso para el tratamiento de cancer
CY1114163T1 (el) Μεθοδοι χρησεως ανταγωνιστων αγγειοπιεσινης με παραγοντες χημειοθεραπειας ανθρακυκλινης για να μειωνεται καρδιοτοξικοτητα ή/και να βελτιωνεται επιβιωση
BRPI0508254A (pt) métodos e composições para o tratamento ou prevenção de distúrbios psiquiátricos com inibidores de cox-2 sozinhos e em combinação com agentes antidepressivos

Legal Events

Date Code Title Description
B25D Requested change of name of applicant approved

Owner name: PSIXUS THERAPEUTICS LIMITED (GB)

B25G Requested change of headquarter approved

Owner name: PSIXUS THERAPEUTICS LIMITED (GB)

B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B25K Entry of change of name and/or headquarter and transfer of application, patent and certificate of addition of invention: republication

Owner name: PSIXUS THERAPEUTICS LIMITED (GB)

B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2468 DE 24/04/2018 POR TER SIDO INDEVIDA.

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B25G Requested change of headquarter approved

Owner name: PSIXUS THERAPEUTICS LIMITED (GB)

B25A Requested transfer of rights approved

Owner name: ACTIMED THERAPEUTICS LTD (GB)

B09B Patent application refused [chapter 9.2 patent gazette]
B12B Appeal against refusal [chapter 12.2 patent gazette]